A note for UK readers

This page explains Germany’s system. Its licences, funding rules and prescribing criteria do not determine access in the UK.

Why can semaglutide be reimbursed for one use but not another?

The G-BA distinguishes use for diabetes from use for weight regulation. The ingredient alone does not determine statutory coverage.

European authorisation sets the indication

EMA's Wegovy information describes prescription treatment alongside dietary and physical-activity support for defined groups. That authorisation permits a medical option; it does not instruct German statutory insurers to pay for every eligible prescription.

The statutory exclusion matters

The G-BA lists Wegovy within the legally excluded category of medicines used for weight regulation. Its explanation distinguishes this from semaglutide products prescribed for authorised diabetes indications. The statutory category is a funding rule, not a description of a person's health needs.

Do not generalise across insurance

The G-BA statement concerns statutory insurance. If you have private insurance, request a written benefit decision for the exact indication and product. A clinician's recommendation alone does not establish what your contract pays.

The UK comparison

Germany's exclusion helps explain why European approval does not create uniform access. It does not determine NHS eligibility, and a German self-pay price cannot establish the cost of a UK prescription with clinical support. Use UK guidance for a personal treatment decision.

Keep these four questions separate

Access

German prescribing and insurance context

Funding

Statutory exclusion for weight-regulation prescribing

Cost context

German EUR self-pay costs do not establish UK prices

Regulatory source

EU authorisation; German national oversight

Compare health systems ↗
Follow the evidence

Sources & further reading

Sources checked . These links support the information above; they do not imply endorsement of this website.

  1. G-BA: Wegovy and the statutory reimbursement exclusion
  2. G-BA: current excluded-medicines framework
  3. EMA: Wegovy medicine overview
A note on this guide

Written for a UK audience by the Health Comparisons editorial team. This page is an information resource and has not been presented as a clinician’s personal recommendation. Discuss treatment decisions with your prescriber.

Read our editorial standards →